micro RNAs in Ovarian Cancer

Öz

Ovarian cancer is the fifth most common cancer death in women. Currently, gynecological examination, evaluation with ultrasound and serum measurements such as CA-125 are the standard for ovarian cancer diagnosis and treatment. However, there is an intense need for new biomarkers that can lead to the diagnosis and treatment of the disease. MicroRNAs (miRNAs), short, protein-coding RNAs, are particularly useful stabilizing endogenous RNAs to become biomarkers in cancer. In this review, it is aimed to investigate the role of miRNAs in ovarian cancer studies conducted to date.

Anahtar Kelimeler

• Ovarian cancer,microRNA,biomarkers

Over Kanserinde mikro RNA’lar

Öz

Over kanseri kadınlarda ölümler arasında 5. en sık ölüm nedeni olan kanserdir. Over kanseri tanı ve tedavisi için günümüzde standart olarak jinekolojik muayene, ultarason ile değerlendirme ve CA-125 gibi serum ölçümleri yer almaktadır. Ancak hem hastalığın tanısı ve tedavisi ile yol gösterebilecek yeni biyobelirteçlere yoğun bir ihtiyaç bulunmaktadır. Kısa, protein kodlamayan RNA’lar olan mikroRNA’lar (miRNA), özellikle kanserde biyobelirteç olmak için oldukça kullanışlı stabil endojen RNA’lardır. Bu derleme kapsamında over kanserinde miRNA’ların bugüne dek yapılan çalışmalarda ki rolünün irdelenmesi amaçlanmıştır.

Anahtar Kelimeler

• Over kanseri,mikroRNA,biyobelirteç

Kaynakça

1. Siegel RL, Milelr KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30.
2. Noone AM, Howlader N, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda,MD, https://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER web site, April 2018. (erişim tarihi: 20.08.2018)
3. Jonas S, Izaurralde SE. Towards a molecular understanding of microRNA-mediated gene silencing. Nat Rev Genet 2015;16:421-433.
4. Zhong X, Coukos G, Zhang L. miRNAs in human cancer. Methods Mol Biol 2012;822: 295-306.
5. Wang X, Ivan M, Hawkins SM. The role of MicroRNA molecules and MicroRNA-regulating machinery in the pathogenesis and progression of epithelial ovarian cancer. Gynecol Oncol 2017;147:481-487.
6. Weidle UH, Birzele F, Kollmorgen G, Nopora A. Potential microRNA-related target for therapeutic intervention with ovarian cancer metastasis. Cancer Genomics Proteomics 2018; 15:1-15.
7. Deb B, Uddin A, Chakraborty S. miRNAs and ovarian cancer: An overview. J Cell Physiol 2018; 233:3846-54.
8. Jackson RJ, Standart N. How do microRNA’s regulate gene expression? Sci STKE. 2007;1:367

9. Xing Z,Li D, Yang L, Xi Y, Su X. MicroRNAs and anticancer drugs. Acta Biochim Biophys Sin 2014;46(3):233-239
10. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297.
11. Zhang L, Huang J, Yang N, et al. microRNAs exhibit high frequency genomic alterations in human cancer, Proc Natl Acad Sci U.S.A. 2006;103:9136-41.
12. Shahab SW, Matyunina LV, Hill CG, et al. The effects of Micro RNA transfections on global patterns of gene expression in ovarian cancer cells are functionally coordinated. BMC Med Genomics 2012;5:33.
13. Nam EJ, Yoon H, Kim SW, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008;14:2690-5.
14. Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007;67:8699-707.
15. Wyman SK, Parkin RK, Mitchell PS, et al. Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One 2009;4:e5311.
16. Calura E, Fruscio R, Paracchini L, et al. MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities. Clin Cancer Res 2013;19:4114-23.
17. Vilming Elgaaen B, Olstad OK, Haug KB, et al. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker. BMC Cancer 2014;14:80.
18. Flavin RJ, Smyth PC, Finn SP, et al. Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. Mod Pathol 2008;21:676-84.
19. Merritt WM, Lin YG, Han LY, et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 2008;359:2641-50.
20. Pampalakis G, Diamandis EP, Katsaros D, et al. Down- regulation of dicer expression in ovarian cancer tissues. Clin Biochem 2010;43:324-7.
21. Resnick KE, Alder H, Hagan JP, et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 2009;112:55-9.
22. Hausler SF, Keller A, Chandran PA, et al. Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Br J Cancer 2010;103:693-700.
23. Zheng H, Zhang L, Zhao Y, et al. Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS One 2013;8:e77853.
24. Kan CW, Howell VM, Hahn MA, et al. Genomic alterations as mediators of miRNA dysregulation in ovarian cancer. Genes Chromosomes Cancer 2015;54:1-19.
25. Chung YW, Bae HS, Song JY, et al. Detection of microRNA as novel biomarkers of epithelial ovarian cancer from the serum of ovarian cancer patients. Int J Gynecol Cancer 2013;23:673-9.
26. Shapira I, Oswald M, Lovecchio J, et al. Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes. Br J Cancer 2014;110:976-83.
27. Langhe R, Norris L, Saadeh FA, et al. A novel serum microRNA panel to discriminate benign from malignant ovarian disease. Cancer Lett 2015;356:628-36.
28. Záveský L, Jandáková E, Turyna R, et al. Evaluation of Cell-Free Urine microRNAs Expression for the Use in Diagnosis of Ovarian and Endometrial Cancers. A Pilot Study. Pathol Oncol Res 2015; 21: 1027-1035.
29. Shahab SW, Matyunina LV, Mezencev R, et al. Evidence for the complexity of microRNA-mediated regulation in ovarian cancer: a systems approach, PloS one 2011;6: e22508.
30. Brouwer J, Kluiver J, de Almeida RC, et al. Small RNA sequencing reveals a comprehensive miRNA signature of BRCA1-associated high-grade serous ovarian cancer. jclinpath-2016-203679. doi: 10.1136/jclinpath-2016-203679.
31. Wu RL, Ali S, Bandyopadhyay S, et al. Comparative Analysis of Differentially Expressed miRNAs and their Down-stream mRNAs in Ovarian Cancer and its Associated Endometriosis. J Cancer Sci Ther 2015;7:258-65
32. Vaksman O, Trope C, Davidson B, et al. Exosome-derived miRNAs and ovarian carcinoma progression. Carcinogenesis 2014; 35:2113-20.
33. Vaksman O, Stavnes HT, Kaern J, et al. miRNA profiling along tumour progression in ovarian carcinoma. J Cell Mol Med 2011;15:1593-602.
34. Vang S, Wu HT, Fischer A, et al. Identification of ovarian cancer metastatic miRNAs. PLoS One 2013;8:e58226
35. Bhattacharya R, Nicoloso M, Arvizo R, et al. MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res 2009;69:9090-5.
36. Polytarchou C, Iliopoulos D, Hatziapostolou M, et al. Akt2 regulates all Akt isoforms and promotes resistance to hypoxia through induction of miR-21 upon oxygen deprivation. Cancer Res 2011;71:4720-31.
37. Hirata Y, Murai N, Yanaihara N, et al. MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma. BMC Cancer 2014;14:799.
38. Cappellesso R, Tinazzi A, Giurici T, et al. Programmed cell death 4 and microRNA 21 inverse expression is maintained in cells and exosomes from ovarian serous carcinoma effusions. Cancer Cytopathol 2014;122:685-93.
39. Shen W, Song M, Liu J, et al. MiR-26a promotes ovarian cancer proliferation and tumorigenesis. PLoS One 2014;9:e86871.
40. Dai F, Zhang Y, Chen Y. Involvement of miR-29b signaling in the sensitivity to chemotherapy in patients with ovarian carcinoma. Hum Pathol 2014;45:1285-93.
41. Jia W, Eneh JO, Ratnaparkhe S, et al. MicroRNA-30c-2* expressed in ovarian cancer cells suppresses growth factor-induced cellular proliferation and downregulates the oncogene BCL9. Mol Cancer Res 2011;9:1732-45.
42. Corney DC, Hwang CI, Matoso A, et al. Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res 2010;16: 1119-28.
43. Seviour EG, Sehgal V, Lu Y, et al. Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. Oncogene 2016; 35:691-701.
44. Cowden Dahl KD, Dahl R, Kruichak JN, et al. The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells. Neoplasia 2009;11:1208-15.
45. Guan Y, Yao H, Zheng Z, et al. MiR-125b targets BCL3 and suppresses ovarian cancer proliferation. Int J Cancer 2011;128:2274-83.
46. Yeh YM, Chuang CM, Chao KC, et al. MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1alpha. Int J Cancer 2013;133:867-78.
47. Parikh A, Lee C, Joseph P, et al. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial- mesenchymal transition. Nat Commun 2014;5:2977.
48. Liu Z, Liu J, Segura MF, et al. MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma. J Pathol 2012;228:204-15
49. Joshi HP, Subramanian IV, Schnettler EK, et al. Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis. Proc Natl Acad Sci U.S.A. 2014;111:5331-6.
50. Bendoraite A, Knouf EC, Garg KS, et al. Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol 2010;116:117-25.
51. Yang D, Sun Y, Hu L, et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell 2013;23:186-99
52. Sun Y, Hu L, Zheng H, et al. MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol 2015;235:25-36.
53. Liu G, Sun Y, Ji P, et al. MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer. J Pathol 2014;233:308-18.
54. Chan JK, Kiet TK, Blansit K, et al. MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer. Gynecol Oncol 2014;133:568-74.
55. Vecchione A, Belletti B, Lovat F, et al. A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci U. S. A. 2013;110:9845-50
56. Boyerinas B, Park SM, Murmann AE, et al. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer 2012;130:1787-97.
57. Ghasabi M, Mansoori B, Mohammadi A, et al. MicroRNAs in cancer drug resistance: Basic evidence and clinical applications. J Cell Physiol 2018;1-1,
58. Shi M, Mu Y, Zhang H, et al. MicroRNA-200 and microRNA-30 family as prognostic molecular signatures in ovarian cancer: A meta-analysis. Medicine (Baltimore). 2018;97(32):e11505
59. Wang J, Yu M, Guan S, et al. Prognostic significance of microRNA-100 in solid tumours: an updated meta-analysis. Onco Targets Ther. 2017;10:493-502.